

L Parker Gregg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5014333/publications.pdf>

Version: 2024-02-01

22
papers

449
citations

933447

10
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

565
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 283-285.	4.5	22
2	Using dipstick urinalysis to predict development of acute kidney injury in patients with COVID-19. <i>BMC Nephrology</i> , 2022, 23, 50.	1.8	9
3	Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19. <i>Kidney Medicine</i> , 2022, 4, 100463.	2.0	4
4	The effects of extracellular volume and intradialytic peripheral resistance changes on ambulatory blood pressure in hemodialysis patients with and without recurrent intradialytic hypertension. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1450-1457.	2.9	3
5	Early eGFR decline after SGLT2i initiation: knowns and unknowns. <i>Kidney International</i> , 2021, 99, 548-550.	5.2	2
6	Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1â€“5. <i>Hypertension</i> , 2021, 77, 948-959.	2.7	14
7	Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. <i>American Journal of Kidney Diseases</i> , 2021, 78, 700-708.e1.	1.9	4
8	Fatigue in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1445-1455.	4.5	53
9	Are All SGLT2 Inhibitors Created Equal?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1309-1311.	4.5	3
10	Considerations in the Study of Body Mass Index Variability. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2395-2397.	6.1	0
11	Diagnosis and Management of Depression in Patients With Kidney Disease. <i>Seminars in Nephrology</i> , 2021, 41, 505-515.	1.6	4
12	Correlates of SGLT-2-inhibitors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. <i>American Heart Journal</i> , 2021, , .	2.7	5
13	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. <i>American Journal of Kidney Diseases</i> , 2020, 75, 457-460.	1.9	6
14	A Systematic Review and Meta-Analysis of Depression and Proteinâ€“Energy Wasting in Kidney Disease. <i>Kidney International Reports</i> , 2020, 5, 318-330.	0.8	20
15	Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 457-464.	2.0	46
16	Screening for Depression in People with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1702-1704.	4.5	3
17	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. <i>Kidney360</i> , 2020, 1, 436-446.	2.1	4
18	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. <i>American Journal of Nephrology</i> , 2019, 50, 37-47.	3.1	31

#	ARTICLE	IF	CITATIONS
19	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. American Journal of Kidney Diseases, 2018, 72, 728-744.	1.9	58
20	Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. American Journal of Nephrology, 2018, 47, 395-405.	3.1	35
21	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
22	Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes. Journal of the American Heart Association, 2017, 6, .	3.7	24